Safety profiles of aromatase inhibitors and selective estrogen-receptor modulators in the treatment of early breast cancer

International Journal of Clinical Oncology

Volumn 13, Issue 5, 2008, Pages 384-394

  Yamamoto, Yutaka ^a   Iwase, Hirotaka ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Adverse events; Aromatase inhibitor; Breast cancer; Joint symptom; Lipid profile; Osteoporosis

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; LETROZOLE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTHROPATHY; BONE DENSITY; BONE STRENGTH; BREAST CANCER; CANDIDIASIS; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CATARACT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG SAFETY; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIUM CANCER; FATIGUE; FRACTURE; HAZARD RATIO; HEART FAILURE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; JOINT STIFFNESS; LIBIDO DISORDER; LIPID METABOLISM; MOOD DISORDER; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MYALGIA; MYCOSIS; NAIL DISEASE; NAUSEA AND VOMITING; NIGHT SWEAT; OSTEOPENIA; OSTEOPOROSIS; PARESTHESIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; URINARY TRACT INFECTION; URINE INCONTINENCE; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINAL HYSTERECTOMY; VENOUS THROMBOEMBOLISM; VISUAL DISORDER; XEROSTOMIA;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FRACTURES, BONE; HUMANS; JOINT DISEASES; LIPID METABOLISM; NEOPLASMS, HORMONE-DEPENDENT; OSTEOPOROSIS; QUALITY OF LIFE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 54849424382     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10147-008-0828-5     Document Type: Review

References (53)

1. Early Breast Cancer Trialist' Group 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717
2. A. Howell J. Cuzick M. Baum 2005 Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 60 62
3. A. Buzdar A. Howell J. Cuzick 2006 Comprehensive sideeffect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial Lancet Oncol 7 633 643
4. A.S. Coates A. Keshaviah B. Thurlimann 2007 Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 J Clin Oncol 25 486 492
5. D. Crivellari Z. Sun A.S. Coates 2008 Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial J Clin Oncol 26 1972 1979
6. R.C. Coombes E. Hall L.J. Gibson 2004 A randomized trial of exemestane after 2 to 3 years of tamoxifen therapy in postmenopausal women with primary breast cancer N Engl J Med 350 1081 1092
7. R.C. Coombes L.S. Kilburn C.F. Snowdon 2007 Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial Lancet 369 559 570
8. R. Jakesz W. Jonat M. Gnant 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial Lancet 366 455 462
9. F. Boccardo A. Rubagotti P. Guglielmini 2006 Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial Ann Oncol 17 Suppl7 vii
10. P.E. Goss J.N. Ingle S. Martino 2005 Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 1262 1271
11. P.E. Goss J.N. Ingle J.L. Pater 2008 Late extended adjuvant treatment with letrozole improves outcome in women with earlystage breast cancer who complete 5 years of tamoxifen J Clin Oncol 26 1948 1955
12. R. Jakesz R. Greil M. Gnant 2007 Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a J Natl Cancer Inst 99 1845 1853
13. E.P. Mamounas J.H. Jeong D.L. Wickerham 2008 Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Sur gical Adjuvant Breast and Bowel Project B-33 trial J Clin Oncol 26 1965 1971
14. M. Saika D. Inoue S. Kido 2001 17 Beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha Endocrinology 142 2205 2212
15. N.K. Shevde A.C. Bendixen K.M. Dienger 2000 Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression Proc Natl Acad Sci U S A 97 7829 7834
16. S. Kousteni T. Bellido L.I. Plotkin 2003 Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity Cell 104 719 730
17. Anonymous (2000) Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement. 17:1-45
18. R. Eastell J.E. Adams R.E. Coleman 2008 Effect of anastrozole on bone mineral density: 5-year results from the Anastrozole, Tamoxifen, Alone or in Combination trial 18233230 J Clin Oncol 26 1051 1057
19. J.F. Forbes J. Cuzick A. Buzdar 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial Lancet Oncol 9 45 53
20. Coleman RE on behalf of ATAC Trialist' Group (2008) Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. J Clin Oncol 26: (May suppl; abstr act 587)
21. R.E. Coleman L.M. Banks S.I. Girgis 2007 Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 119 127
22. E.A. Perez R.G. Josse K.I. Pritchard 2006 Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17 J Clin Oncol 24 3629 3635
23. P.E. Lonning J. Geisler L.E. Krag 2005 Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer J Clin Oncol 23 5126 5137
24. J. Geisler P.E. Lonning L.E. Krag 2006 Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study Eur J Cancer 42 2968 2975
25. B.E. Hillner J.N. Ingle R.T. Chlebowski 2003 American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer J Clin Oncol 21 4042 4057
26. P.P. Donnellan S.L. Douglas D.A. Cameron 2001 Aromatase inhibitors and arthralgia J Clin Oncol 19 2767
27. K.D. Crew H. Greenlee J. Capodice 2007 Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer J Clin Oncol 25 3877 3883
28. A. Buzdar 2006 Clinical features of joint symptoms observed in the 'Arimidex' Tamoxifen, Alone or in Combination (ATAC) trial J Clin Oncol 2006 Annual Meeting Proceedings Part I 124 551
29. L. Morales S. Pans R. Paridaens 2007 Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging Breast Cancer Res Treat 104 87 91
30. L. Morales S. Pans K. Verschueren 2008 Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome J Clin Oncol 26 3147 3152
31. W. Dietrich A. Haitel G. Holzer 2006 Estrogen receptorbeta is the predominant estrogen receptor subtype in normal human synovia J Soc Gynecol Investig 13 512 517
32. A.S. Chagin D. Chrysis M. Takigawa 2006 Locally produced estrogen promotes fetal rat metatarsal bone growth; an effect mediated through increased chondrocyte proliferation and decreased apoptosis J Endocrinol 188 193 203
33. P. Hoegh-Andersen L.B. Tanko T.L. Andersen 2004 Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application Arthritis Res Ther 6 R169 180
34. F. Pansini P. Albertazzi G. Bonaccorsi 1994 The menopausal transition: a dynamic approach to the pathogenesis of neurovegetative complaints Eur J Obstet Gynecol Reprod Biol 57 103 109
35. Fontaine C, Meulemans A, Huizing M, et al. (2008) Tolerance of adjuvant letrozole outside of clinical trials. Breast
36. Y. Hozumi Y. Hakamata H. Sasanuma 2002 Effects of anastrozole on lipid metabolism compared with tamoxifen in rats Breast Cancer Res Treat 76 131 136
37. P.E. Goss S. Qi A.M. Cheung 2004 Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats Clin Cancer Res 10 5717 5723
38. P.E. Goss S. Qi R.G. Josse 2004 The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats Bone 34 384 392
39. S. Banerjee I.E. Smith L. Folkerd 2005 Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the IMPACT trial Ann Oncol 16 1632 168
40. S. Sawada K. Sato M. Kusuhara 2005 Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer Acta Oncol 44 134 141
41. M.S. Elisaf E.T. Bairaktari C. Nicolaides 2001 Effect of letrozole on the lipid profile in postmenopausal women with breast cancer Eur J Cancer 37 1510 1513
42. K.M. Wasan P.E. Goss P.H. Pritchard 2005 The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L) Ann Oncol 16 707 715
43. G. Atalay L. Dirix L. Biganzoli 2004 The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, "Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients" Ann Oncol 15 211 217
44. C. Markopoulos A. Polychronis V. Zobolas 2005 The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study Breast Cancer Res Treat 93 61 66
45. Breast International Group 1-98 Collaborative Group 2005 A Comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer New Engl J Med 353 2747 2757
46. B. Thurlimann A. Keshaviah A.S. Coates 2005 A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2747 2757
47. C.M. Bender S.M. Sereika A.M. Brufsky 2007 Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer Menopause 14 995 998
48. B. Gerber A. Krause T. Reimer 2006 Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology Clin Cancer Res 12 1245 1250
49. L. Fallowfield D. Cella J. Cuzick 2004 Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial J Clin Oncol 22 4261 4271
50. D. Cella L. Fallowfield P. Barker 2006 Quality of life of postmenopausal women in the ATAC ("Arimidex", Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for early breast cancer Breast Cancer Res Treat 100 273 284
51. L.J. Fallowfield J.M. Bliss L.S. Porter 2006 Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer J Clin Oncol 24 910 917
52. T.J. Whelan P.E. Goss J.N. Ingle 2005 Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women J Clin Oncol 23 6931 6940
53. R. Thomas M. Williams C. Marshall 2008 Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women Br J Cancer 98 1494 1499